Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Mayo Clinic discover important clue to new treatments for lymphoma, breast and colon cancers


Mayo Clinic researchers discover that key cancer gene cbp doesn’t work alone; Important clue to targeting new treatments for lymphoma, breast and colon cancers

Mayo Clinic cancer researchers have discovered a key partnership between two genes in mice that prevents the development of cancer of the lymph nodes, known as T-cell leukemia or lymphoma.

This first-time finding provides researchers with a promising target for designing new anti-cancer drugs that fight lymphomas, as well as other cancers in which this partnership exists, including breast and colon cancers.

The Mayo Clinic research report appears as the cover story in today’s edition of the journal, Cancer Cell, ( Jan van Deursen, Ph.D., a specialist in pediatric cancers with the Department of Pediatrics and a member of the Mayo Clinic Cancer Center, led the research team.

According to Dr. van Deursen, the Mayo Clinic cancer research team used specially-bred laboratory mice to demonstrate three things not previously known about the development of these types of cancer. They are the first to:
  • Provide laboratory evidence that the gene CBP is a tumor suppressor -- and that the lack of CBP contributes to the formation of lymphoma.

  • Demonstrate that the absence of CBP works in partnership with low levels of a protein called p27Kip1. When these two conditions are present, lymphoma development accelerates in mice.

  • Discover that two compounds -- Cyclin E and Skp2 -- control p27Kip1 levels.

"We not only found the tumor suppressor, we also showed what other gene defects need to occur in the same cell for cancer to progress," says Dr. van Deursen. "Cancer is not the result of a single defect, but is related to a combination of defects and events," he explains. "To find the best treatment, it’s vital to discover what combinations of changes have occurred with the cell to transform it from a normal cell into a cancer cell."

Lymphoma belongs to the hematologic malignancies group of cancers because it involves blood, bone marrow and lymph nodes. In general, it is one of the more common cancers and it is increasing in the United States. Each year about 50,000 Americans are diagnosed with some form of lymphoma, and another 30,000 die from the cancer.

Background Analogy: Cancer as a River and the Search for its Headwaters

Cancer researchers liken cancer to a river with directional flow. Like a river, cancer flows downstream toward production of disease. What researchers want to find is the upstream headwaters -- the point of origin that eventually leads to cancer.

They look for the earliest "upstream" cellular irregularities that contribute to dangerous "downstream" conditions. In this study, Mayo Clinic researchers discovered a previously unknown early, upstream event in the cancer process -- that the compounds Cyclin E and Skp2 are upstream elements that control the downstream level of p27Kip1. They found that when p27Kip1 levels are low, and when combined with the absence of CBP, conditions favor cancer.

"Low levels of p27Kip1 are often associated with human cancers and with very poor prognosis," says Dr. van Deursen. "We have shown in our research the mechanism by which p27Kip1 gets altered. Now that we know this mechanism, we can design treatments to keep levels of p27Kip1 from going down."

Dr. van Deursen notes that altered levels of p27Kip1 are not the result of a defective gene. Rather, the altered levels are the indirect result of high levels of the upstream molecules, Cyclin E and Skp2.

"If we can prevent these indirect upstream effects from happening, then the undesirable downstream events will not occur," he says.

From this finding, the Mayo Clinic cancer researchers conclude that a cooperative relationship exists between the loss of CBP and depressed levels of p27Kip1 to produce cancer.

A grant to Mayo Clinic from the Department of Defense funded this research study. Researchers from St. Jude Children’s Research Hospital in Memphis, Tenn., also contributed to the investigation.

Mary Lawson | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>